Phase II/III clinical trial - Hématologie Leucémie

AML LI-1
Hématologie Leucémie
Ouvert depuis le: 04.18.2019
Site: Saint-Cloud
Public cible
Adulte
A PROGRAMME OF DEVELOPMENT FOR OLDER PATIENTS WITH ACUTE MYELOID LEUKAEMIA AND HIGH RISK MYELODYSPLASTIC SYNDROME
Description de l'essai

The LI-1 Protocol is an international ongoing therapeutic evaluation program for elderly patients with high-risk AML and MDS who are considered ineligible for conventional intensive chemotherapy. Patients are initially included in a randomized multi-arm Phase II trial, which compares multiple new therapeutic options to the standard treatment (low-dose Aracytine).